Indivior Pharmaceuticals, Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $356.0 million (+13.4% year over year) and diluted EPS of $1.12. It usually reports 29–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
356
+13.4%
|
137
+226.2%
|
1.12
+239.4%
|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
343
+13.6%
|
122
+577.8%
|
0.98
+600.0%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
317
+19.2%
|
89
+89.4%
|
0.69
+81.6%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
358
|
102
+385.7%
|
0.78
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
314
|
42
|
0.33
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
302
|
18
|
0.14
|
|
Apr 24, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
266
|
47
|
0.38
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INDV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1625297
- Former names
- Indivior Pharmaceuticals, Inc. (until Nov 2, 2026); INDIVIOR PLC (until Jan 8, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.